Videos

Futura Medical hails positive phase III results as it prepares for US FDA sign-off for ED gel

Futura Medical delighted with Cooper Health deal for MED3000

Futura Medical PLC "in a good place" as it moves towards launch of MED3000

Futura Medical signs South Korean licensing deal for erectile dysfunction gel MED3000

Futura Medical PLC reaches licensing deal for erectile dysfunction gel in Brazil and Mexico

Futura Medical’s CEO discusses £12m fundraising for MED3000

Proactive Investor interview with James Barder

Proactive Interview with Ken James Futura Medical 'at final administrative stages of getting approval' for MED3000 in Europe

Futura Medical Announces Investment and Joint Collaboration to Commercialise MED3000 in China and South East Asia

James Barder Interview with Proactive Investor

James Barder talks to Proactive Investor

James Barder interview with Proactive Investor

Ken James interview with Proactive Investor

James Barder, Chief Executive interview with Proactive Investor’s Andrew Scott

James Barder, Chief Executive interview with Proactive Investor’s Andrew Scott

Ken James speaks to Proactive Investor’s Andrew Scott following positive initial discussions with EU regulators after an extensive internal evaluation of the clinical data from the Phase 3 study (“FM57”).

Ken James speaks to Proactive London's Andrew Scott following the read-out from the phase III clinical trial of its erectile dysfunction gel.

Fireside chat with Ken James & Dr Wayne Hellstrom

James Barder caught up with Proactive London's Andrew Scott to talk through the company's interim results.

James Barder introduces Futura and its lead product MED2005

Fireside chat with Professor David Ralph and Ken James

Research & Development seminar on MED2005

Interview of Ken James, Head of R&D, by Proactive Investors in which he discusses milestone for Futura Medical

Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses their Phase 3 trial

Interview of Ken James, Head of R&D, by Proactive Investors in which he discusses new safety data on lead treatment

Interview of Angela Hildreth, FD and COO, by Proactive Investors in which she discusses the first patient in its Phase 3 clinical study of MED2005

Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses MED2005

Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the lead asset MED2005

Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the first Phase 3 efficacy trial for MED2005

Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the progress across Futura's portfolio of products.

Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the recent article published by the Journal of Sexual Medicine.

Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the start of the PK study and provides a regulatory, clinical and commercial update.

Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the positive market research data on MED2005 announced on 16 October 2017.

Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the Interim results for the period ending 30 June 2017 including the Phase 3 programme for MED2005 and the strategy for CSD500.

Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the change of priorities which sees Futura Medical distributor terminate licensing agreement.

Video Interview of James Barder discussing a 'critical step' in the development of MED2005

Video Interview of James Barder discussing the Preliminary results for the year ended 31 December 2016

Video Interview of James Barder discussing the significant interest for MED2005, Futura’s erectile dysfunction gel based on Ipsos research

Video Interview of James Barder discussing the UK licensing agreement for its pain relief gel TPR100 and the launch of CSD500 in Saudi Arabia

Interview with Ken James Futura Medical confirm US Food & Drug Administration agreement 'hot on heels' of EU regulatory steps